grepcent public filings, reorganized for comparison

NU SKIN ENTERPRISES, INC. (NUS)

CIK: 0001021561. SIC: 5122 Wholesale-Drugs, Proprietaries & Druggists' Sundries. Latest 10-K as of: 2026-02-13.

SIC breadcrumb: Wholesale Trade > Wholesale Trade - Nondurable Goods > SIC 5122 Wholesale-Drugs, Proprietaries & Druggists' Sundries

SEC company page: https://www.sec.gov/edgar/browse/?CIK=1021561. Latest filing source: 0001140361-26-005130.

Informational only. Descriptive public-record data — not a rating, forecast, or investment advice. See Disclaimer.

At a glance

FY2025 · period end 2025-12-31 · filed 2026-02-13 · accession 0001140361-26-005130 · source: SEC companyfacts

Revenue
1,485,159,000 USD verified
Net income
160,204,000 USD verified
Assets
1,405,313,000 USD verified
Free cash flow
46,009,000 USD computed
Net margin
10.79% computed
Operating margin
4.43% computed
Revenue YoY
-14.26% computed
ROE
19.90% computed

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

Peer & cluster context

Peer percentile fingerprint

NUS ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC major-group 51; per-ratio N printed.NUS ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC major-group 51; per-ratio N printed.RatioNUSPeer medianPercentileNNet margin10.8%1.2%9522Operating margin4.4%2.5%7021Revenue growth-14.3%2.4%522FCF margin3.1%2.0%7122ROE19.9%8.7%8818ROA11.4%3.3%9522Liabilities / equity0.751.811818Current ratio2.081.586222

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC major-group 51 Wholesale Trade - Nondurable Goods, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

Selected Fundamentals

MetricValueUnitFYFiled
Revenue1,485,159,000USD20252026-02-13
Net income160,204,000USD20252026-02-13
Assets1,405,313,000USD20252026-02-13

Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-13. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001021561.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

Download these verified figures (annual + quarterly, with per-value filing provenance): JSON · CSV

Flow metrics use full-year FY periods from 10-K/10-K/A filings; balance-sheet metrics use FY-end instants. Free cash flow = operating cash flow - capital expenditures. Missing metrics are omitted rather than fabricated.

Metric2016201720182019202020212022202320242025
Revenue2,207,797,0002,279,099,0002,679,008,0002,420,416,0002,581,934,0002,695,669,0002,225,659,0001,969,131,0001,732,084,0001,485,159,000
Net income143,086,000129,437,000121,887,000173,553,000191,355,000147,266,000104,778,0008,595,000-146,594,000160,204,000
Operating income231,104,000274,483,000240,860,000267,426,000257,564,000233,992,000110,847,00048,268,000-151,585,00065,763,000
Gross profit1,707,340,0001,777,021,0002,044,868,0001,838,996,0001,923,906,0002,020,446,0001,594,744,0001,357,281,0001,181,851,0001,031,398,000
Diluted EPS2.552.362.163.103.632.862.070.17-2.953.18
Operating cash flow275,263,000302,555,000202,738,000177,931,000379,141,000141,582,000108,062,000118,639,000111,742,00080,286,000
Capital expenditures50,221,00060,156,00070,371,00066,067,00063,823,00068,615,00059,056,00058,490,00041,583,00034,277,000
Dividends paid78,438,00076,058,00080,581,00082,189,00078,387,00076,272,00077,015,00077,622,00011,927,00011,834,000
Share buybacks247,208,00071,731,00069,565,000825,000144,334,00080,420,00070,045,00013,011,0000.0020,040,000
Assets1,474,045,0001,589,872,0001,694,446,0001,769,006,0001,957,076,0001,906,480,0001,820,970,0001,808,626,0001,468,914,0001,405,313,000
Liabilities809,975,000885,276,000912,579,000893,717,0001,062,805,000993,708,000923,674,000986,658,000817,459,000600,073,000
Stockholders' equity664,070,000704,596,000781,867,000875,289,000894,271,000912,772,000897,296,000821,968,000651,455,000805,240,000
Cash and cash equivalents357,246,000426,399,000386,911,000335,630,000402,683,000339,593,000264,725,000256,057,000186,883,000238,630,000
Free cash flow225,042,000242,399,000132,367,000111,864,000315,318,00072,967,00049,006,00060,149,00070,159,00046,009,000

Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

Metric2016201720182019202020212022202320242025
Net margin6.48%5.68%4.55%7.17%7.41%5.46%4.71%0.44%-8.46%10.79%
Operating margin10.47%12.04%8.99%11.05%9.98%8.68%4.98%2.45%-8.75%4.43%
Return on equity21.55%18.37%15.59%19.83%21.40%16.13%11.68%1.05%-22.50%19.90%
Return on assets9.71%8.14%7.19%9.81%9.78%7.72%5.75%0.48%-9.98%11.40%
Liabilities / equity1.221.261.171.021.191.091.031.201.250.75
Current ratio1.791.741.822.071.661.652.122.131.822.08

Industry Peer Context

Each number-line places NUS against the min, median, and max of latest reported values among companies in the same SIC industry when at least three peers report that ratio.

Net margin peer context

NUS Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 5122; peer count 5.NUS Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 5122; peer count 5.5 SIC peersMin 0.5%Median 1.2%Max 10.8%NUS 10.8%

Operating margin peer context

NUS Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 5122; peer count 5.NUS Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 5122; peer count 5.5 SIC peersMin 0.8%Median 1.5%Max 9.5%NUS 4.4%

ROA peer context

NUS ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 5122; peer count 5.NUS ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 5122; peer count 5.5 SIC peersMin 2.0%Median 5.8%Max 11.4%NUS 11.4%

Financial Bridges

Waterfall figures reconcile reported SEC companyfacts components. Missing bridges are omitted when required components are not present for the same fiscal year.

Income statement bridge from reported figures

NUS FY2025 income statement bridge from reported figures.NUS FY2025 income statement bridge from reported figures.NUS income bridgeFY2025: revenue to net incomeSource: SEC companyfacts FY2025.Income statement bridgeReported amount$0.0B$1.0B$2.0B$1.5BRevenue-$453.8MCost$1.0BGross-$965.6MOpEx$65.8MOperating+$94.4MOther/tax$160.2MNet income

Figure provenance: SEC companyfacts FY 2025. Revenue: accession 0001140361-26-005130; concept RevenueFromContractWithCustomerExcludingAssessedTax; source concepts us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | Gross profit: accession 0001140361-26-005130; concept GrossProfit; source concepts us-gaap:GrossProfit | Operating income: accession 0001140361-26-005130; concept OperatingIncomeLoss; source concepts us-gaap:OperatingIncomeLoss | Net income: accession 0001140361-26-005130; concept NetIncomeLoss; source concepts us-gaap:NetIncomeLoss

Free cash flow = operating cash flow - capital expenditures

NUS FY2025 free cash flow bridge from reported figures.NUS FY2025 free cash flow bridge from reported figures.NUS free cash flow bridgeFY2025: operating cash flow less capital expendituresSource: SEC companyfacts FY2025.Free cash flow bridgeReported amount$0.0B$125.0M$250.0M$80.3MOperating cash flow-$34.3MCapex$46.0MFree cash flow

Figure provenance: SEC companyfacts FY 2025. Operating cash flow: accession 0001140361-26-005130; concept NetCashProvidedByUsedInOperatingActivities; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities | Capital expenditures: accession 0001140361-26-005130; concept PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | Free cash flow: accession 0001140361-26-005130; concept NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment; source concepts us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

Financial Charts

NUS revenue, last 5 periods. Source: SEC companyfacts FY2025.NUS revenue, last 5 periods. Source: SEC companyfacts FY2025.NUS RevenueLatest point: FY2025 = $1.5BSource: SEC companyfacts FY2025.Fiscal yearReported revenue$0.0B$2.0B$4.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001140361-26-005130; filed 2026-02-13. Concept: RevenueFromContractWithCustomerExcludingAssessedTax. Source concepts: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

NUS net income, last 5 periods. Source: SEC companyfacts FY2025.NUS net income, last 5 periods. Source: SEC companyfacts FY2025.NUS Net incomeLatest point: FY2025 = $160.2MSource: SEC companyfacts FY2025.Fiscal yearNet income-$250.0M$0.0B$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001140361-26-005130; filed 2026-02-13. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

NUS operating income, last 5 periods. Source: SEC companyfacts FY2025.NUS operating income, last 5 periods. Source: SEC companyfacts FY2025.NUS Operating incomeLatest point: FY2025 = $65.8MSource: SEC companyfacts FY2025.Fiscal yearOperating income-$250.0M$0.0B$500.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001140361-26-005130; filed 2026-02-13. Concept: OperatingIncomeLoss. Source concepts: us-gaap:OperatingIncomeLoss.

NUS gross profit, last 5 periods. Source: SEC companyfacts FY2025.NUS gross profit, last 5 periods. Source: SEC companyfacts FY2025.NUS Gross profitLatest point: FY2025 = $1.0BSource: SEC companyfacts FY2025.Fiscal yearGross profit$0.0B$2.0B$4.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001140361-26-005130; filed 2026-02-13. Concept: GrossProfit. Source concepts: us-gaap:GrossProfit.

NUS diluted eps, last 5 periods. Source: SEC companyfacts FY2025.NUS diluted eps, last 5 periods. Source: SEC companyfacts FY2025.NUS Diluted EPSLatest point: FY2025 = $3.18/shareSource: SEC companyfacts FY2025.Fiscal yearDiluted EPS (USD/share)-$4.00/share$0.00/share$6.00/shareFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001140361-26-005130; filed 2026-02-13. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

NUS operating cash flow, last 5 periods. Source: SEC companyfacts FY2025.NUS operating cash flow, last 5 periods. Source: SEC companyfacts FY2025.NUS Operating cash flowLatest point: FY2025 = $80.3MSource: SEC companyfacts FY2025.Fiscal yearOperating cash flow$0.0B$125.0M$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001140361-26-005130; filed 2026-02-13. Concept: NetCashProvidedByUsedInOperatingActivities. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities.

NUS capital expenditures, last 5 periods. Source: SEC companyfacts FY2025.NUS capital expenditures, last 5 periods. Source: SEC companyfacts FY2025.NUS Capital expendituresLatest point: FY2025 = $34.3MSource: SEC companyfacts FY2025.Fiscal yearCapital expenditures$0.0B$125.0M$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001140361-26-005130; filed 2026-02-13. Concept: PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

NUS dividends paid, last 5 periods. Source: SEC companyfacts FY2025.NUS dividends paid, last 5 periods. Source: SEC companyfacts FY2025.NUS Dividends paidLatest point: FY2025 = $11.8MSource: SEC companyfacts FY2025.Fiscal yearDividends paid$0.0B$125.0M$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001140361-26-005130; filed 2026-02-13. Concept: PaymentsOfDividendsCommonStock. Source concepts: us-gaap:PaymentsOfDividendsCommonStock.

NUS share buybacks, last 5 periods. Source: SEC companyfacts FY2025.NUS share buybacks, last 5 periods. Source: SEC companyfacts FY2025.NUS Share buybacksLatest point: FY2025 = $20.0MSource: SEC companyfacts FY2025.Fiscal yearShare buybacks$0.0B$125.0M$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001140361-26-005130; filed 2026-02-13. Concept: PaymentsForRepurchaseOfCommonStock. Source concepts: us-gaap:PaymentsForRepurchaseOfCommonStock.

NUS assets, last 5 periods. Source: SEC companyfacts FY2025.NUS assets, last 5 periods. Source: SEC companyfacts FY2025.NUS AssetsLatest point: FY2025 = $1.4BSource: SEC companyfacts FY2025.Fiscal yearAssets$0.0B$1.0B$2.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001140361-26-005130; filed 2026-02-13. Concept: Assets. Source concepts: us-gaap:Assets.

NUS liabilities, last 5 periods. Source: SEC companyfacts FY2025.NUS liabilities, last 5 periods. Source: SEC companyfacts FY2025.NUS LiabilitiesLatest point: FY2025 = $600.1MSource: SEC companyfacts FY2025.Fiscal yearLiabilities$0.0B$500.0M$1.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001140361-26-005130; filed 2026-02-13. Concept: Liabilities. Source concepts: us-gaap:Liabilities.

NUS stockholders' equity, last 5 periods. Source: SEC companyfacts FY2025.NUS stockholders' equity, last 5 periods. Source: SEC companyfacts FY2025.NUS Stockholders' equityLatest point: FY2025 = $805.2MSource: SEC companyfacts FY2025.Fiscal yearStockholders' equity$0.0B$500.0M$1.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001140361-26-005130; filed 2026-02-13. Concept: StockholdersEquity. Source concepts: us-gaap:StockholdersEquity.

NUS cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2025.NUS cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2025.NUS Cash and cash equivalentsLatest point: FY2025 = $238.6MSource: SEC companyfacts FY2025.Fiscal yearCash and cash equivalents$0.0B$250.0M$500.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001140361-26-005130; filed 2026-02-13. Concept: CashAndCashEquivalentsAtCarryingValue. Source concepts: us-gaap:CashAndCashEquivalentsAtCarryingValue.

NUS free cash flow, last 5 periods. Source: SEC companyfacts FY2025.NUS free cash flow, last 5 periods. Source: SEC companyfacts FY2025.NUS Free cash flowLatest point: FY2025 = $46.0MSource: SEC companyfacts FY2025.Fiscal yearFree cash flow$0.0B$125.0M$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2025-12-31; accession 0001140361-26-005130; filed 2026-02-13. Concept: NetCashProvidedByUsedInOperatingActivities - PaymentsToAcquirePropertyPlantAndEquipment. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities; us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

As-reported value updates

No tracked differences above grepcent's stated thresholds and capped precision rule were found between the earliest XBRL-filed value and the value currently on file for the standardized annual metrics grepcent tracks.

Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-10. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001021561.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

QuarterEnd DateRevenueNet IncomeDiluted EPSMethod
2022-Q32022-09-30-0.51reported discrete quarter
2023-Q12023-03-310.23reported discrete quarter
2023-Q22023-06-300.54reported discrete quarter
2023-Q32023-09-30498,772,000-36,955,000-0.74reported discrete quarter
2023-Q42023-12-31488,640,0007,282,000derived Q4 = FY annual - nine-month YTD
2024-Q12024-03-31417,306,000-533,000-0.01reported discrete quarter
2024-Q22024-06-30439,081,000-118,258,000-2.38reported discrete quarter
2024-Q32024-09-30430,145,0008,302,0000.17reported discrete quarter
2024-Q42024-12-31445,552,000-36,105,000derived Q4 = FY annual - nine-month YTD
2025-Q12025-03-31364,490,000107,515,0002.14reported discrete quarter
2025-Q22025-06-30386,138,00021,119,0000.43reported discrete quarter
2025-Q32025-09-30364,211,00017,079,0000.34reported discrete quarter
2025-Q42025-12-31370,320,00014,491,000derived Q4 = FY annual - nine-month YTD
2026-Q12026-03-31320,608,0001,836,0000.04reported discrete quarter
2026-Q22026-06-30320,112,000-249,798,000-5.14reported discrete quarter

Quarterly Charts

NUS quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q2.NUS quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q2.NUS Quarterly RevenueLatest point: 2026-Q2 = $320.1MSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Revenue$0.0B$250.0M$500.0M2023-Q32023-Q42024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001140361-26-032055; filed 2026-08-10. Concept: RevenueFromContractWithCustomerExcludingAssessedTax. Source concepts: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

NUS quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q2.NUS quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q2.NUS Quarterly Net incomeLatest point: 2026-Q2 = -$249.8MSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Net income-$250.0M$0.0B$250.0M2023-Q32023-Q42024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32025-Q42026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001140361-26-032055; filed 2026-08-10. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

NUS quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q2.NUS quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q2.NUS Quarterly Diluted EPSLatest point: 2026-Q2 = -$5.14/shareSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Diluted EPS (USD/share)-$6.00/share$0.00/share$4.00/share2022-Q32023-Q12023-Q22023-Q32024-Q12024-Q22024-Q32025-Q12025-Q22025-Q32026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-06-30; accession 0001140361-26-032055; filed 2026-08-10. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

Business

Read NUS's verbatim Item 1 Business section from its latest 10-K: Business.

Risk Factors

Read NUS's verbatim Item 1A Risk Factors from its latest 10-K: Risk Factors.

Latest quarter (10-Q)

Latest 10-Q source: 0001140361-26-032055.

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Confidence: high. Filing date: 2026-08-10. Report date: 2026-06-30.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, that represent our current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not
limited to, statements of management’s expectations regarding our performance, growth, initiatives, strategies, products, ingredients, product introductions and offerings, product portfolio optimization, restructuring and exit activities,
acquisitions, the integration and performance of acquired companies, divestitures, opportunities and risks; statements of management’s expectations, plans and beliefs regarding global economic conditions and our markets (including India), sales
force, sales compensation plan and customer base; statements regarding government policies and regulations relating to our industry, including government policies and regulations in or related to the United States and Mainland China; statements
regarding tariffs and trade policies; statements regarding the outcome of litigation, audits, investigations, and other legal or regulatory matters; statements of projections and expectations regarding future sales, expenses, operating results,
taxes, duties, capital expenditures, sources and uses of cash, foreign-currency fluctuations or devaluations, repatriation of undistributed earnings, and other financial items; statements regarding the payment of future dividends and stock
repurchases; accounting estimates and assumptions; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “enable,”
“project,” “anticipate,” “determine,” “estimate,” “intend,” “plan,” “goal,” “objective,” “targets,” “become,” “likely,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words. We undertake no obligation to
publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. We caution and advise readers that these statements are based on assumptions that may not be
realized and involve important risks and uncertainties that could cause actual results to differ materially from the expectations and beliefs contained herein. For a summary of these risks, see the risk factors included in our Annual Report on Form
10-K for the 2025 fiscal year and in any of our subsequent Securities and Exchange Commission filings, including this Quarterly Report.

The following Management’s Discussion and Analysis should be read in conjunction with our consolidated financial statements and related notes and Management’s Discussion and Analysis included in our Annual Report on
Form 10-K for the 2025 fiscal year, and our other reports filed with the Securities and Exchange Commission through the date of this Quarterly Report.

Overview

Revenue for the three-month period ended June 30, 2026 decreased 17.1% to $320.1 million, compared to $386.1 million in the prior-year period, and revenue for the six-month period ended June 30, 2026 decreased 14.6%
to $640.7 million, compared to $750.6 million in the prior-year period. Our revenue in the second quarter of 2026 was negatively impacted by 1.0% from foreign-currency fluctuations. Our Customers, Paid Affiliates and Sales Leaders declined 14%, 8%
and 9%, respectively, on a year-over-year basis.

The declines for the three- and six-month periods ended June 30, 2026 were largely driven by the continued macroeconomic challenges we have been facing in our markets, which have negatively impacted consumer spending
and customer acquisition. Our priorities for 2026 focus on business model optimization, driven by the continued rollout of enhancements to our sales performance plan, the continued launch of our Prysm iO
intelligent wellness platform and business expansion into India. Our early learnings from the Prysm iO have resulted in a shift in the strategy from a device placement focus to an assessment model that is
more conducive to in-person engagement. In addition, from our preview in India we have identified the need to simplify the model in advance of our full market opening, which is now slated for the first half of 2027.

Earnings per share for the second quarter of 2026 decreased to $(5.14), compared to $0.43 in the prior-year period. Earnings per share for the first six months of 2026 decreased to $(5.12),
compared to $2.59 in the prior-year period. Our second quarter 2026 earnings per share were negatively impacted by an impairment charge of $78.9 million and a $167.5 million valuation allowance associated with our U.S. deferred tax assets, as
well as the decline in revenue. Our earnings per share for the first six months of 2026 were negatively impacted by the second quarter impairment charge, second quarter valuation allowance, charges associated with our first quarter of 2026 wind
down of our separate BeautyBio business and decline in revenue. Our 2025 earnings per share benefited from the January 2025 sale of our Mavely business, which generated a pre-tax gain of approximately $176.2 million, partially offset by the
associated taxes, an intangible asset group impairment of $25.1 million in our Rhyz Other segment and a non-cash loss on equity investment of $28.1 million.

20

Table of Contents

Segment Results

We report our business in nine segments to reflect our current management approach. These segments consist of our seven geographic Nu Skin segments—Americas, Mainland China, Southeast Asia/Pacific, Japan, Europe
& Africa, South Korea and Hong Kong/Taiwan—and our two Rhyz segments—Manufacturing and Rhyz Other. The Nu Skin Other category includes miscellaneous corporate revenue and related adjustments.

The following table sets forth revenue for the three- and six-month periods ended June 30, 2026 and 2025 for each of our reportable segments (U.S. dollars in thousands):

Three Months EndedConstant-Six Months EndedConstant-
June 30,CurrencyJune 30,Currency
20262025ChangeChange(1)20262025ChangeChange(1)
Nu Skin
Americas$59,763$72,946(18.1)%(15.8)%$117,581$142,004(17.2)%(14.2)%
Mainland China45,95653,224(13.7)%(18.7)%91,104100,999(9.8)%(14.6)%
Southeast Asia/Pacific43,25750,834(14.9)%(16.3)%88,731103,006(13.9)%(16.5)%
Japan38,14344,550(14.4)%(5.5)%77,88287,315(10.8)%(4.9)%
Europe & Africa32,31737,328(13.4)%(15.2)%63,53570,349(9.7)%(15.0)%
Hong Kong/Taiwan26,07427,527(5.3)%(3.6)%53,53155,974(4.4)%(4.8)%
South Korea25,62034,068(24.8)%(19.0)%50,94966,583(23.5)%(20.2)%
Nu Skin Other79427(81.5)%(81.5)%(155)956(116.2)%(116.2)%
Total Nu Skin271,209320,904(15.5)%(14.2)%543,158627,186(13.4)%(13.4)%
Rhyz
Manufacturing46,36960,400(23.2)%(23.2)%91,294115,690(21.1)%(21.1)%
Rhyz Other2,5344,834(47.6)%(47.6)%6,2687,752(19.1)%(19.1)%
Total Rhyz48,90365,234(25.0)%(25.0)%97,562123,442(21.0)%(21.0)%
Total$320,112$386,138(17.1)%(16.1)%$640,720$750,628(14.6)%(14.6)%
Column 1Column 2
(1)Constant-currency revenue change is a non-GAAP financial measure. See “Non-GAAP Financial Measures,” below.

The tables below set forth summarized financial information for each of our reportable segments for the three- and six-month periods ended June 30, 2026 and 2025 (U.S.
dollars in thousands). Segment contribution excludes certain intercompany charges, specifically royalties, license fees, transfer pricing and other miscellaneous items. We use segment contribution to measure the
portion of profitability that the segment managers have the ability to control for their respective segments. For additional information regarding our segments and the calculation of segment contribution, see Note 11 to the consolidated financial
statements contained in this report.

Three Months Ended June 30, 2026
Nu SkinRhyz
MainlandSoutheastEurope &Hong Kong/SouthRhyzTotal
AmericasChinaAsia/PacificJapanAfricaTaiwanKoreaManufacturingOtherSegments
Revenue$59,763$45,956$43,257$38,143$32,317$26,074$25,620$46,369$2,534$320,033
Cost of sales15,0378,28310,5187,8327,7844,2555,44140,873478100,501
Other segment items33,58226,33525,08019,38519,94413,94912,6956,0732,503159,546
Segment contribution$11,144$11,338$7,659$10,926$4,589$7,870$7,484$(577)$(447)$59,986
Segment contribution as a percentage of revenue18.6%24.7%17.7%28.6%14.2%30.2%29.2%(1.2)%(17.6)%18.7%

21

Table of Contents

[Excerpt truncated for page length; source filing is linked above.]

Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: 0001140361-26-005130. The complete FY 2025 MD&A is published at /company/NUS/mda/fy2025/.

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Confidence: high. Filing date: 2026-02-13. Report date: 2025-12-31.

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and related notes, which are included in this
Annual Report on Form 10-K.

Business Overview

Our Products

Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of premium-quality beauty and wellness solutions in nearly 50 markets worldwide. In 2025, our revenue of $1.5
billion was primarily generated by our two primary product categories: beauty products and wellness products. We operate in the direct selling channel, primarily utilizing person-to-person marketing to
promote and sell our products, including through the use of social and digital platforms.

In addition to our core Nu Skin business, we also explore new areas
of synergistic and adjacent growth through our strategic investment arm known as Rhyz Inc., which we formed in 2018. Our Rhyz businesses primarily consist of consumer, technology and manufacturing companies. In 2025, the Rhyz companies
generated $223.6 million, or 15%, of our 2025 reported revenue (excluding sales to our core Nu Skin business). As discussed further in “Rhyz Companies,” below, in January 2025 we sold one of our Rhyz businesses that accounted for $69.6
million of our 2024 reported revenue. Our Rhyz companies enable us to optimize our cost of goods, improve lead times, diversify our revenue mix, and create synergies for our brands.

Our Global Operations

In 2025, we generated approximately 26% of our revenue from the United States (consisting of our Nu Skin United States and Rhyz businesses) and the remainder from our international markets. Given
the size of our international operations, our results, as reported in U.S. dollars, are often impacted by foreign-currency fluctuations; in 2025, our revenue was negatively impacted 0.8% from foreign-currency fluctuations compared to 2024. Our
results also can be impacted by global economic, political, demographic and business trends and conditions.

A Global Network of Customers, Paid Affiliates and Sales Leaders

As of December 31, 2025, we had 748,796 persons who purchased directly from the company during the previous three months (“Customers”). Our Customer numbers include members of our sales force who
made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force. We believe a significant majority of Customers purchase our
products primarily for personal or family consumption but are not actively pursuing the opportunity to generate supplemental income by actively and consistently marketing and reselling products.

Our revenue is highly influenced by the number and productivity of our Sales Leaders. “Sales Leaders” are our Brand Affiliates, as well as sales employees and independent marketers in Mainland
China, who achieve certain qualification requirements. Our reported Sales Leaders number is the three-month average of our monthly Sales Leaders as of the end of each month of the quarter.

As we continue to focus on customer acquisition and social commerce, we believe our number of Paid Affiliates is an important indicator of consumer purchasing activity in our business. “Paid
Affiliates” are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the previous three months. Paid Affiliates power our social commerce model and are a bridge to attracting new
customers and nurturing relationships and community.

We have been successful in attracting and motivating our sales force by:

Column 1Column 2Column 3
developing and marketing innovative, technologically and scientifically advanced products;
Column 1Column 2Column 3
providing compelling initiatives and strong support; and
Column 1Column 2Column 3
offering an attractive sales compensation, incentive, and recognition rewards structure.

Our global sales force helps us to rapidly introduce products and penetrate our markets with modest up-front promotional expense. We rely on our sales force to create consumer demand for our
products, as opposed to a traditional approach of advertising-generated consumer awareness. Our approach is particularly effective with products that benefit from personal education and demonstration. Similar to other companies in our industry,
we experience relatively high turnover among our sales force.

49

Table of Contents

To enhance customer retention, we have developed product subscription and loyalty programs that provide incentives for consumers to commit to
purchase a specific amount of product on a monthly basis. Several of our products are conducive to subscriptions. For example, Prysm iO
and its accompanying mobile application are designed to generate subscription sales. All purchases under these programs are subject to our standard product payment and return policies. We believe these subscription and loyalty programs have
improved consumer retention, have had a stabilizing impact on revenue and have helped generate recurring sales.

Product Innovation

Our sales force markets and sells our products, and attracts others to the opportunity, based on the distinguishing benefits and innovative characteristics of our products. As a result, we
leverage our scientific expertise and product development resources to introduce innovative beauty, wellness and anti-aging products. Our sales force is increasingly using social media to market and sell our products. To continue to leverage
social media, it is imperative that we develop demonstrable products that are unique and engaging to younger consumers. We strive to strike a balance between the expenses associated with our scientific expertise and sales compensation with a
competitive price point.

Any delays or difficulties in introducing compelling products or attractive initiatives or tools into our markets may have a negative impact on our revenue and our number of Customers, Paid
Affiliates and Sales Leaders.

Our Product Launch Process

Prior to making a product generally available for purchase in a market, we often do one or more introductory offerings of the product, such as a preview of the product to our Sales Leaders or other product
introduction or promotion. We refer to the entire process, beginning with the introductory offering through general availability of the product, as a product launch or our product launch process. The timing of the launch of a particular product
often varies from market to market depending on such factors as customer demand, affiliate brand focus, product registration or other local legal requirements, and product availability in our supply chain.

Sales Leader previews and other product introductions and promotions sometimes generate significant activity and a high level of purchasing, which can result in a higher-than-normal increase in revenue, Customers,
Paid Affiliates and Sales Leaders during the quarter and skew year-over-year and sequential comparisons. We believe our product launch process attracts new Customers, Paid Affiliates and Sales Leaders to our business, increases consumer trial,
and provides us with important marketing and forecasting information about our products. Please refer to Item 1A. Risk Factors for more information on risks related to our product launch process.

Income Statement Presentation

We report revenue in nine segments, and we translate revenue from each market’s local currency into U.S. dollars using weighted-average exchange
rates. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products. All revenue associated with a contract is recognized when we satisfy our performance obligations under the contract. We
recognize revenue by transferring the promised products to the customer, with revenue primarily recognized at shipping point, the point in time the customer obtains control of the products. We recognize revenue for shipping and handling
charges at the time the products are delivered to or picked up by the customer. In most markets, we offer a return policy that allows our sales force to return unopened and unused product for up to 30 days for a full refund, or 12 months
subject to a 10% restocking fee. Reported revenue is net of returns, which have historically been less than 5% of annual revenue. Sales taxes and value added taxes in foreign jurisdictions that are collected from customers and remitted to
governmental authorities are accounted for on a net basis and therefore are excluded from net sales.

Cost of sales primarily consists of:

Column 1Column 2Column 3
cost of products purchased from third-party vendors;
Column 1Column 2Column 3
cost of self-manufactured products;
Column 1Column 2Column 3
cost of adjustments to inventory carrying value;
Column 1Column 2Column 3
cost of manufacturing and distribution occupancy cost;
Column 1Column 2Column 3
labor cost associated with the manufacturing process;
Column 1Column 2Column 3
freight cost of shipping products to our sales force and import duties for the products; and
Column 1Column 2Column 3
royalties and related expenses for licensed technologies.

50

Table of Contents

For markets other than Mainland China, in 2025, we sourced most of our beauty products and wellness products from trusted third-party suppliers and manufacturers. In Mainland China, we operate
manufacturing facilities where we produce the majority of our beauty and wellness products sold in Mainland China. We also produce some products at these facilities that are exported to other markets. In addition, our Rhyz Manufacturing entities
in the United States are producing some of our products. Cost of sales and gross profit, on a consolidated basis, may fluctuate as a result of changes in the ratio between self-manufactured products and products sourced from third-party vendors.
In addition, because we purchase a significant amount of our goods in U.S. dollars and recognize revenue in local currencies, our gross margin is subject to exchange rate risks. Because our gross margins vary from product to product and due to
higher pricing in some markets, changes in product mix and geographic revenue mix can impact our gross margin on a consolidated basis.

Selling expenses are our most significant expense and are classified as operating expenses. Selling expenses include sales commissions paid to our
sales force, special incentives, costs for incentive trips, cost of sales force conventions and other rewards, as well as salaries, service fees, benefits, bonuses and other labor and unemployment expenses we pay to our sales force in Mainland
China. The sales force conventions are held in various markets worldwide, which we generally expense in the period in which they are incurred. Because our various sales force conventions are not held during each fiscal year, or in the same
period each year, their impact on our general and administrative expenses may vary from year to year and from quarter to quarter. For example, we currently plan to hold a global convention approximately every other year. We held our last
in-person global convention in the third quarter of 2024, with an east event in South Korea and a west event in the United States, and we currently plan to hold our
next in-person global convention in the third quarter of 2026. These conventions have significant expenses associated with them. Because we have not incurred expenses for these conventions during e

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A or browse all MD&A years.

MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

FDA-approved drug applications

Applications listed under this company's exact-matched sponsor name. Approved applications only.

No resolved FDA applications were found for this company under the exact-unique, approved-only publish rule.

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

This list covers FDA applications whose listed sponsor name maps to this company by an exact-unique match; applications listed under sponsor names not mapped to this company (subsidiaries, name variants, joint ventures) are absent.

Macro cross-references for NUS

Indicators mapped to this company's SIC classification (industry 5122 Wholesale-Drugs, Proprietaries & Druggists' Sundries) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

Macro-to-micro threads including this sector: Money & trade, Industrial orders & inventories, Trade & external.

All 71 macro indicators →

For LLMs & downloads

Markdown twin: /company/NUS.md · JSON record: /company/NUS.json · verified financials: JSON / CSV · machine TOC for the whole site: /llms.txt